India Generic Drug Manufacturing Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

The India generic drug manufacturing market was valued at USD 27.92 Billion in 2025 and is expected to grow at a CAGR of 5.90%, reaching USD 49.53 Billion by 2035. The government incentives, patent expirations, and strong export demand are propelling the market, supported by cost-efficient production capabilities and growing global partnerships in affordable pharmaceutical supply chains across the region.

Q1 2026 Market Updates

The India generic drug manufacturing market, which accounts for approximately 20 percent of global supply by volume with over 60,000 generic brands across 60 therapeutic categories, faces unprecedented supply chain disruption from the Iran-US-Israel conflict. India imports about 50 percent of its crude oil through the Strait of Hormuz, and the near-total closure of this waterway, with commercial traffic down 90 percent since early March 2026, has created a dual crisis affecting both inbound raw material supply and outbound pharmaceutical exports. Brent crude exceeding USD 120 per barrel is not merely a fuel cost issue for Indian manufacturers; oil is the petrochemical feedstock for solvents, plastics, packaging materials, glycerin, and phenols that are essential building blocks for drug manufacturing.

The logistics disruption is severe and multi-dimensional. Air freight rates out of India have already surged 200 to 350 percent on key export routes, while sea shipments face cancelled sailings, rerouting around Africa, trapped containers, and skyrocketing insurance premiums. Ocean freight rerouting via the Cape of Good Hope adds approximately 49 days to transit times for active pharmaceutical ingredient exports to Europe and North America. Nearly half of US generic drug prescriptions are manufactured in India and transit through waters affected by the conflict, creating a direct link between the Strait of Hormuz closure and medicine availability in major Western markets.

Input cost inflation is cascading through the generic drug value chain. Active pharmaceutical ingredients contain key starting materials derived from petrochemical processes, which now cost more and take longer to ship to Indian manufacturing facilities. Chemical surcharges of up to 30 percent on packaging materials including blister packs, bottles, and film coatings are compressing margins for an industry that already operates on thin pricing. The HSBC India PMI has fallen to its lowest since October 2022, reflecting broader manufacturing sector contraction. Indian pharmaceutical exports, a critical foreign exchange earner, face delays and cost increases that could persist if the conflict extends beyond the near term.

Despite these headwinds, India's generic drug sector shows resilience and continued innovation. Dr. Reddy's Laboratories announced plans in July 2025 to launch generic semaglutide across 87 countries, while the March 2026 patent expiry has triggered a wave of domestic GLP-1 receptor agonist manufacturing. The G7 pledge on March 30 to safeguard supply chains and the IEA's emergency oil stock release on March 11 provide some stabilisation. The Indian government's PLI scheme and Make in India initiatives are accelerating domestic API production to reduce import dependency and strengthen the nation's position as the pharmacy of the world.

Key Takeaways

Government:

• The Indian government's PLI scheme is accelerating domestic active pharmaceutical ingredient production to reduce import dependency on petrochemical-derived key starting materials disrupted by the Strait of Hormuz closure.
• The G7 pledged on March 30, 2026, to safeguard critical supply chains, and the IEA's emergency oil stock release on March 11 provides partial relief for India's energy-dependent pharmaceutical manufacturing sector importing 50 percent of crude oil through the affected waterway.
• Indian trade authorities are working to establish alternative logistics corridors and negotiate emergency shipping arrangements to maintain pharmaceutical export timelines to the United States and Europe amid air freight surges of 200 to 350 percent.

Market:

• Air freight rates out of India have surged 200 to 350 percent on key pharmaceutical export routes, while ocean freight rerouting adds 49 days to transit times for API shipments, directly threatening India's role in supplying nearly half of US generic prescriptions.
• Petrochemical-derived manufacturing inputs including solvents, glycerin, phenols, and packaging materials face chemical surcharges of up to 30 percent, compressing margins for generic drug manufacturers already operating on thin pricing in competitive global markets.
• India's generic drug innovation continues with Dr. Reddy's planning semaglutide launches across 87 countries and a wave of domestic GLP-1 manufacturing following the March 2026 patent expiry, demonstrating sector resilience despite supply chain disruptions.

Procurement:

• Procurement teams face extended lead times of up to 49 additional days for key starting materials and petrochemical-derived API inputs due to shipping diversions, requiring advance ordering and significantly expanded raw material inventory positions.
• Sourcing costs for solvents, packaging resins, and pharmaceutical excipients have risen sharply as oil-derived petrochemical feedstocks become more expensive and harder to ship, while insurance premiums for maritime shipments through conflict zones have escalated.
• Procurement strategies are diversifying API sourcing across multiple global suppliers, establishing alternative shipping routes through Indian Ocean corridors, and building strategic inventory buffers to ensure uninterrupted generic drug manufacturing operations.

Key Trends and Insights

• India contributed approximately 6% of the global generic drug manufacturing market revenue during the historical period, reflecting its strong position as a leading pharmaceutical producer.
• The simple generics segment dominated the market by drug type, capturing an estimated 65% revenue share in the historical period.
• Retail pharmacies segment is expected to lead the market by distribution channel in the forecast period.

Market Size and Forecast

• Market Size (2025): USD 27.92 Billion
• Projected Market Size (2035): USD 49.53 Billion
• CAGR (2026-2035): 5.90%